{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:14:26Z","timestamp":1775074466473,"version":"3.50.1"},"reference-count":158,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The first cases of AIDS in Spain were reported in 1982. Since then over 85,000 persons with AIDS have been cumulated, with 60,000 deaths. Current estimates for people living with HIV are of 145,000, of whom 20% are unaware of it. This explains the still high rate of late HIV presenters. Although the HIV epidemic in Spain was originally driven mostly by injection drug users, since the year 2000 men having sex with men (MSM) account for most new incident HIV cases. Currently, MSM represent over 80% of new yearly HIV diagnoses. In the 80s, a subset of young doctors and nurses working at Internal Medicine hospital wards became deeply engaged in attending HIV-infected persons. Before the introduction of antiretrovirals in the earlier 1990s, diagnosis and treatment of opportunistic infections was their major task. A new wave of infectious diseases specialists was born. Following the wide introduction of triple combination therapy in the late 1990s, drug side effects and antiretroviral resistance led to built a core of highly devoted HIV specialists across the country. Since then, HIV medicine has improved and currently is largely conducted by multidisciplinary teams of health care providers working at hospital-based outclinics, where HIV-positive persons are generally seen every six months. Antiretroviral therapy is currently prescribed to roughly 75,000 persons, almost all attended at clinics belonging to the government health public system. Overall, the impact of HIV\/AIDS publications by Spanish teams is the third most important in Europe. HIV research in Spain has classically been funded mostly by national and European public agencies along with pharma companies. Chronologically, some of the major contributions of Spanish HIV research are being in the field of tuberculosis, toxoplasmosis, leishmaniasis, HIV variants including HIV-2, drug resistance, pharmacology, antiretroviral drug-related toxicities, coinfection with viral hepatitis, design and participation in clinical trials with antiretrovirals, immunopathogenesis, ageing, and vaccine development.<\/jats:p>","DOI":"10.3390\/v10060293","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T03:07:42Z","timestamp":1527736062000},"page":"293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["AIDS Clinical Research in Spain\u2014Large HIV Population, Geniality of Doctors, and Missing Opportunities"],"prefix":"10.3390","volume":"10","author":[{"given":"Vicente","family":"Soriano","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, La Paz University Hospital, 28046 Madrid, Spain"},{"name":"UNIR Health Sciences School, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-9867","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Ramos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General University Hospital, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose V.","family":"Fernandez-Montero","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Crosshouse, Kilmarnock KA2 0BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0140-6736(83)92117-7","article-title":"AIDS in haemophilia patients in Spain","volume":"321","author":"Lissen","year":"1983","journal-title":"Lancet"},{"key":"ref_2","first-page":"645","article-title":"AIDS in a male residing in Barcelona","volume":"81","author":"Estruch","year":"1983","journal-title":"Med. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jinf.2016.01.017","article-title":"Cohorte de la Red de Investigaci\u00f3n en Sida, Spain. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004\u20132013","volume":"72","author":"Moreno","year":"2016","journal-title":"J. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/377562","article-title":"Lessons from the history of the HIV\/AIDS epidemic among Spanish drug injectors","volume":"37","author":"Bravo","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.eimc.2015.04.007","article-title":"Bibliometric analysis of the Spanish scientific production in infectious diseases and microbiology","volume":"34","author":"Ramos","year":"2016","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJM199203053261004","article-title":"Tuberculous meningitis in patients infected with the HIV","volume":"326","author":"Berenguer","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/00002030-199107000-00021","article-title":"Multifocal splenic abscesses caused by Mycobacterium tuberculosis in HIV-infected drug users","volume":"5","author":"Soriano","year":"1991","journal-title":"AIDS"},{"key":"ref_8","unstructured":"Centers for Disease Control and Prevention (1996). Multidrug-resistant tuberculosis outbreak on an HIV ward\u2014Madrid, Spain, 1991\u20131995. Morb. Mortal. Wkly. Rep., 45, 330\u2013333."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(97)07567-3","article-title":"Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection","volume":"350","author":"Guerrero","year":"1997","journal-title":"Lancet"},{"key":"ref_10","first-page":"231","article-title":"Management of tuberculosis in HIV-infected patients","volume":"14","author":"Curran","year":"2012","journal-title":"AIDS Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-122-10-199505150-00004","article-title":"Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV","volume":"122","author":"Podzamczer","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-123-3-199508010-00003","article-title":"Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS","volume":"123","author":"Podzamczer","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/cid\/ciq197","article-title":"Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis","volume":"52","author":"Lejeune","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/504872","article-title":"Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: Results of an open, randomized, multicenter clinical trial","volume":"43","author":"Miro","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00002030-200003100-00011","article-title":"Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy","volume":"14","author":"Soriano","year":"2000","journal-title":"AIDS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.10.2.298","article-title":"Leishmania and HIV coinfection: The first 10 years","volume":"10","author":"Alvar","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10096-005-1342-6","article-title":"Leishmaniasis as an opportunistic infection in HIV-infected patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region","volume":"24","author":"Pasquau","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/clinids\/19.1.48","article-title":"Gastrointestinal leishmaniasis in HIV-infected patients: Report of five cases and review","volume":"19","author":"Laguna","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-199302000-00011","article-title":"Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears","volume":"7","author":"Laguna","year":"1993","journal-title":"AIDS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00002030-199906180-00009","article-title":"Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B","volume":"13","author":"Laguna","year":"1999","journal-title":"AIDS"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: A randomized pilot study","volume":"52","author":"Laguna","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","first-page":"32","article-title":"Treatment options for visceral leishmaniasis and HIV coinfection","volume":"18","year":"2016","journal-title":"AIDS Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1089\/aid.2010.0247","article-title":"Changing rate of non-B subtypes and coinfection with hepatitis B\/C viruses in newly diagnosed HIV type 1 individuals in Spain","volume":"27","author":"Soriano","year":"2011","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1089\/aid.2008.0166","article-title":"Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain","volume":"25","author":"Garrido","year":"2009","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.1423-0410.1996.7110066.x","article-title":"First case of HIV-1 group O infection in Spain","volume":"71","author":"Soriano","year":"1996","journal-title":"Vox Sang."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/aid.2005.21.602","article-title":"Treatment response and drug resistance in patients infected with HIV type 1 group O viruses","volume":"21","author":"Rodes","year":"2005","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/aid.2008.0222","article-title":"Raltegravir and etravirine are active against HIV type 1 group O","volume":"25","author":"Briz","year":"2009","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_28","first-page":"212","article-title":"The burden of neglected HIV-2 and HTLV-1 infections in Spain","volume":"17","author":"Caballero","year":"2015","journal-title":"AIDS Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00002030-198909000-00013","article-title":"HIV-1, HIV-2 and HTLV-I infection in high-risk groups in Spain","volume":"3","author":"Soriano","year":"1989","journal-title":"AIDS"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/QAD.0000000000001485","article-title":"HIV-2 epidemic in Spain: Challenges and missing opportunities","volume":"31","author":"Cabezas","year":"2017","journal-title":"AIDS"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2015.01.001","article-title":"Dolutegravir for the treatment of HIV-2 infection","volume":"64","author":"Cabezas","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/088922201750102481","article-title":"Molecular evidence of homosexual transmission of HIV type 2 in Spain","volume":"17","author":"Cilla","year":"2001","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1086\/431204","article-title":"Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2","volume":"41","author":"Toro","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.00160-10","article-title":"Resistance Platform of the Spanish AIDS Research Network (ResRIS). Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy","volume":"54","author":"Poveda","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0b013e328331a4b8","article-title":"Resistance Platform of the Spanish AIDS Research Network (ResRIS). Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database","volume":"24","author":"Poveda","year":"2010","journal-title":"AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1742-4690-9-68","article-title":"Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir\/emtricitabine therapy","volume":"9","author":"Betancor","year":"2012","journal-title":"Retrovirology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/jac\/dkt146","article-title":"Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes","volume":"68","author":"Anta","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/QAD.0b013e3283584500","article-title":"Resistance Platform of the Spanish AIDS Research Network. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies","volume":"27","author":"Anta","year":"2013","journal-title":"AIDS"},{"key":"ref_39","first-page":"39","article-title":"HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines","volume":"11","author":"Anta","year":"2009","journal-title":"AIDS Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/431203","article-title":"Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1","volume":"41","author":"Rodriguez","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E485","DOI":"10.1111\/1469-0691.12011","article-title":"Analysis of transmitted drug resistance in Spain in the years 2007\u20132010 documents a decline in mutations to the non-nucleoside drug class","volume":"18","author":"Monge","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Monge, S., Guillot, V., Alvarez, M., Chueca, N., Stella, N., Pe\u00f1a, A., Delgado, R., C\u00f3rdoba, J., Aguilera, A., and Vidal, C. (2014). Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090710"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Barreiro","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/QAD.0b013e32833202e2","article-title":"Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations","volume":"24","author":"Labarga","year":"2010","journal-title":"AIDS"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study","volume":"48","author":"Labarga","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/17425255.2014.930128","article-title":"Pharmacogenetics of antiretroviral therapy","volume":"10","author":"Barreiro","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_47","first-page":"15","article-title":"Pharmacogenetics of adverse effects due to antiretroviral drugs","volume":"12","author":"Vidal","year":"2010","journal-title":"AIDS Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"ref_49","first-page":"126","article-title":"Disorders of body fat distribution in HIV-1-infected patients","volume":"11","author":"Moreno","year":"2009","journal-title":"AIDS Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/hiv.12011","article-title":"Impact of switching from zidovudine\/lamivudine to tenofovir\/emtricitabine on lipoatrophy: The RECOMB study","volume":"14","author":"Ribera","year":"2013","journal-title":"HIV Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Domingo, P., Gutierrez, M., Gallego-Escuredo, J.M., Torres, F., Mateo, G., Villarroya, J., de los Santos, I., Domingo, J.C., Villarroya, F., and Del Rio, L. (2014). Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV\/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089088"},{"key":"ref_52","first-page":"112","article-title":"Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy","volume":"14","author":"Domingo","year":"2012","journal-title":"AIDS Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ofw097","DOI":"10.1093\/ofid\/ofw097","article-title":"HIV as a chronic disease: Evaluation and management of non-AIDS-defining conditions","volume":"3","author":"Miralles","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection","volume":"349","author":"Arnaiz","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/605440","article-title":"Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)","volume":"49","author":"Negredo","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1468-1293.2011.00917.x","article-title":"Lipid profiles for nevirapine vs. atazanavir\/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-na\u00efve HIV-1-infected patients (the ARTEN study)","volume":"12","author":"Podzamczer","year":"2011","journal-title":"HIV Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e328359f29c","article-title":"Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir","volume":"26","author":"Llibre","year":"2012","journal-title":"AIDS"},{"key":"ref_59","first-page":"25","article-title":"The changing epidemiology of liver disease in HIV patients","volume":"15","author":"Soriano","year":"2013","journal-title":"AIDS Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(10)60829-X","article-title":"Treatment of medical, psychiatric, and substance use comorbidities in people infected with HIV who use drugs","volume":"376","author":"Altice","year":"2010","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nrgastro.2013.165","article-title":"Treating hepatitis C in injection drug users","volume":"10","author":"Soriano","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2893.2007.00903.x","article-title":"Liver cirrhosis in HIV-infected patients: Prevalence, aetiology and clinical outcome","volume":"15","author":"Castellares","year":"2008","journal-title":"J. Viral Hepat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinids\/23.3.585","article-title":"Interferon alpha for the treatment of chronic hepatitis C in patients infected with Human Immunodeficiency Virus","volume":"23","author":"Soriano","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Romero","year":"2003","journal-title":"AIDS"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial","volume":"23","author":"Miralles","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/infdis\/jis449","article-title":"Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-\u03b1 for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial","volume":"206","author":"Labarga","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/jac\/dkp479","article-title":"EuroSIDA: Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe","volume":"65","author":"Soriano","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/592171","article-title":"Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe","volume":"198","author":"Soriano","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/QAD.0b013e32834babb3","article-title":"Hepatitis delta in HIV-infected individuals in Europe","volume":"25","author":"Soriano","year":"2011","journal-title":"AIDS"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e3282f8b46f","article-title":"Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients","volume":"196","author":"Labarga","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients","volume":"24","author":"Naggie","year":"2010","journal-title":"AIDS"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/infdis\/jir113","article-title":"Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in HIV-HCV-coinfected patients receiving antiretroviral therapy","volume":"203","author":"Barreiro","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/501021","article-title":"Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: Assessment using transient elastometry and the role of HCV genotype 3","volume":"42","author":"Barreiro","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/656811","article-title":"Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV","volume":"51","author":"Medrano","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic HCV-1 in patients with HIV","volume":"159","author":"Sulkowski","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/QAD.0000000000000579","article-title":"Faldaprevir and pegylated interferon \u03b1-2a\/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV","volume":"29","author":"Dieterich","year":"2015","journal-title":"AIDS"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New Therapies for Hepatitis C Virus Infection","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/QAD.0b013e328362fe42","article-title":"Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B","volume":"27","author":"Plaza","year":"2013","journal-title":"AIDS"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/cid\/ciu167","article-title":"Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients","volume":"58","author":"Vispo","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/QAD.0000000000001424","article-title":"Hepatitis delta and HIV infection","volume":"31","author":"Soriano","year":"2017","journal-title":"AIDS"},{"key":"ref_85","first-page":"35","article-title":"Non-alcoholic fatty liver disease in HIV infection","volume":"19","author":"Pineda","year":"2017","journal-title":"AIDS Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1600-6143.2012.04028.x","article-title":"Outcome of HCV\/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study","volume":"12","author":"Miro","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/hep.28321","article-title":"HIV infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma","volume":"63","author":"Forner","year":"2016","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/lt.24741","article-title":"HIV-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study","volume":"23","author":"Forner","year":"2017","journal-title":"Liver Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1517\/14656566.2016.1112790","article-title":"New hepatitis C therapies for special patient populations","volume":"17","author":"Soriano","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.qai.0000221683.44940.62","article-title":"Severe liver disease associated with prolonged exposure to antiretroviral drugs","volume":"42","author":"Maida","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350801300111","article-title":"Antiretroviral-associated portal hypertension: A new clinical condition? Prevalence, predictors and outcome","volume":"13","author":"Maida","year":"2008","journal-title":"Antivir. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/QAD.0b013e3283389e26","article-title":"Non-cirrhotic portal hypertension in HIV-infected patients: Unique clinical and pathological findings","volume":"24","author":"Vispo","year":"2010","journal-title":"AIDS"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1310\/hct0906-440","article-title":"Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV\/HCV co-infected patients","volume":"9","author":"Vispo","year":"2008","journal-title":"HIV Clin. Trials"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/cid\/cit001","article-title":"Genetic determinants of idiopathic non-cirrhotic portal hypertension in HIV-infected patients","volume":"56","author":"Vispo","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/01.qai.0000243091.40490.fd","article-title":"Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy","volume":"43","author":"Barreiro","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/humrep\/dem226","article-title":"Is natural conception a valid option for HIV-serodiscordant couples?","volume":"22","author":"Barreiro","year":"2007","journal-title":"Hum. Reprod."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e4398","DOI":"10.1097\/MD.0000000000004398","article-title":"Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study","volume":"95","author":"Baza","year":"2016","journal-title":"Medicine"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Das, M., Chu, P.L., Santos, G., Scheer, S., Vittinghoff, E., McFarland, W., and Colfax, G. (2010). Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011068"},{"key":"ref_99","first-page":"54","article-title":"Antiretroviral drugs for pre-exposure prophylaxis of HIV infection","volume":"14","author":"Barreiro","year":"2012","journal-title":"AIDS Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0000000000001262","article-title":"Using PrEP, losing condoms? PrEP promotion may undermine safe sex","volume":"30","author":"Alaei","year":"2016","journal-title":"AIDS"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1310\/hct0802-98","article-title":"Outbreak of syphilis, but not of acute hepatitis, C.; among HIV-infected homosexual men in Madrid","volume":"8","author":"Barreiro","year":"2007","journal-title":"HIV Clin. Trials"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/liv.12212","article-title":"Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain","volume":"33","author":"Plaza","year":"2013","journal-title":"Liver Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/cid\/ciu813","article-title":"Is it time to rethink syphilis control?","volume":"60","author":"Boyd","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_104","first-page":"118","article-title":"More pre-exposure prophylaxis for rising HIV infection?","volume":"16","author":"Barreiro","year":"2014","journal-title":"AIDS Rev."},{"key":"ref_105","first-page":"54","article-title":"Transmission of multi-drug resistant HIV-1 despite antiretroviral prophylaxis","volume":"19","author":"Soriano","year":"2017","journal-title":"AIDS Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1310\/0CJ5-2ABQ-CB00-6MR6","article-title":"SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals","volume":"3","author":"Soriano","year":"2002","journal-title":"HIV Clin. Trials"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/135965350200700202","article-title":"A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine\/ lamivudine in HIV-infected naive patients (the Combine Study)","volume":"7","author":"Podzamczer","year":"2002","journal-title":"Antivir. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/aid.2006.0029","article-title":"Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: The ELADI study","volume":"23","author":"Palacios","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1086\/592114","article-title":"Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: Final analysis (48 weeks) of a prospective, randomized, non-inferiority clinical trial, GESIDA 3903","volume":"47","author":"Berenguer","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.antiviral.2009.11.008","article-title":"Similar antiviral efficacy and tolerability between efavirenz and lopinavir\/ritonavir, administered with abacavir\/lamivudine (Kivexa), in antiretroviral-naive patients: A 48-week, multicentre, randomized study (Lake Study)","volume":"85","author":"Echeverria","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/aid.2009.0105","article-title":"Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a non-nucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: Three-year results (The Advanz Trial): A randomized, controlled trial","volume":"26","author":"Manzardo","year":"2010","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN trial","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","article-title":"Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/QAI.0000000000000567","article-title":"Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-infected patients starting efavirenz, lopinavir-ritonavir, or atazanavir-ritonavir plus tenofovir\/emtricitabine: Final 48-week results (the Advanz-3 trial)","volume":"69","author":"Miro","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/cid\/ciu898","article-title":"Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial","volume":"60","author":"Martinez","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-139-2-200307150-00007","article-title":"Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial","volume":"139","author":"Negredo","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/135965350501000708","article-title":"Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial","volume":"10","author":"Barrios","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00126334-200501010-00009","article-title":"Lopinavir\/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)","volume":"38","author":"Negredo","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","article-title":"Lopinavir\/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)","volume":"40","author":"Arribas","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkm413","article-title":"Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial","volume":"61","author":"Soriano","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/QAI.0b013e31819a226f","article-title":"Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV\/r-containing HAART: The ATAZIP study","volume":"51","author":"Mallolas","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3851\/IMP1519","article-title":"Treatment simplification to once daily darunavir\/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients","volume":"15","author":"Valle","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dks540","article-title":"Switching to lopinavir\/ritonavir with or without abacavir\/lamivudine in lipoatrophic patients treated with zidovudine\/abacavir\/lamivudine","volume":"68","author":"Bernardino","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: A randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir and ritonavir plus lamivudine versus triple treatment with atazanavir and ritonavir plus two nucleos[t]ides in patients who are HIV1 infected, on antiretroviral treatment, and virologically stable (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Rubio","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir and ritonavir plus lamivudine versus triple treatment with lopinavir and ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/aid.2015.0248","article-title":"Efficacy and safety of treatment simplification to lopinavir\/ritonavir or darunavir\/ritonavir monotherapy: A randomized clinical trial","volume":"32","author":"Santos","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_130","first-page":"844","article-title":"Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals","volume":"72","author":"Negredo","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"39","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/QAD.0000000000000773","article-title":"IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection","volume":"29","author":"Real","year":"2015","journal-title":"AIDS"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00002030-200405210-00004","article-title":"Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection","volume":"18","author":"Toro","year":"2004","journal-title":"AIDS"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/JVI.00419-16","article-title":"Long-term spontaneous control of HIV-1 is related to low frequency of infected cells and inefficient viral reactivation","volume":"90","author":"Noel","year":"2016","journal-title":"J. Virol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/QAD.0000000000001050","article-title":"Rate and predictors of progression in elite and viremic HIV-1 controllers","volume":"30","author":"Leon","year":"2016","journal-title":"AIDS"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/ciw833","article-title":"Spanish AIDS Research Network HIV-Controllers Cohort. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers","volume":"64","author":"Hua","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"Massanella","year":"2010","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2217\/pgs.14.1","article-title":"Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients","volume":"15","author":"Vidal","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Deeks","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4690-6-27","article-title":"The Spanish HIV BioBank: A model of cooperative HIV research","volume":"6","author":"Gallego","year":"2009","journal-title":"Retrovirology"},{"key":"ref_141","first-page":"107","article-title":"Catch me if you can\u2014The race between HIV and neutralizing antibodies","volume":"17","author":"Dietrich","year":"2015","journal-title":"AIDS Rev."},{"key":"ref_142","first-page":"166ra2","article-title":"A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication","volume":"5","author":"Climent","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jac\/dkv046","article-title":"Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1","volume":"70","author":"Mothe","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"G\u00f3mez, C., Perdiguero, B., Garc\u00eda-Arriaza, J., Cepeda, V., S\u00e1nchez-Sorzano, C., Mothe, B., Jim\u00e9nez, J.L., Mu\u00f1oz-Fern\u00e1ndez, M.\u00c1., Gatell, J.M., and L\u00f3pez Bernaldo de Quir\u00f3s, J.C. (2015). A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141456"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e02182-16","DOI":"10.1128\/JVI.02182-16","article-title":"HIV\/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived VLPs or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-specific B and T cell immune functions in non-human primates","volume":"91","author":"Perdiguero","year":"2017","journal-title":"J. Virol."},{"key":"ref_146","unstructured":"Soriano, V., Gonzalez-Lahoz, J., and Guardiola, J.M. (2011). Manual del SIDA, Permanyer Publisher."},{"key":"ref_147","unstructured":"Gatell, J., Clotet, B., Podzamczer, D., Mir\u00f3, J.M., and Mallolas, J. (2016). Guia Pr\u00e1ctica del SIDA, Mason Publisher."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1473-3099(15)00063-8","article-title":"Prediction of geriatric HIV in 2030","volume":"15","author":"Vance","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ageing\/afx013","article-title":"Frailty and physical function in older HIV-infected patients","volume":"46","author":"Dronda","year":"2017","journal-title":"Age Ageing"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrmicro2223","article-title":"Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs","volume":"7","author":"Coiras","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2352-3018(15)00083-1","article-title":"CCR5 \u039432 homozygous cord blood allogeneic transplantation in a patient with HIV: A case report","volume":"2","author":"Duarte","year":"2015","journal-title":"Lancet HIV"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"De Blonde, J., Sasse, A., Del Amo, J., Burns, F., Delpech, V., Cowan, S., Levoy, M., Keith, L., Pharris, A., and Amato-Gauci, A. (2015). Restricted access to antiretroviral treatment for undocumented migrants: A bottle neck to control the HIV epidemic in the EU\/EEA. BMC Public Health, 15.","DOI":"10.1186\/s12889-015-2571-y"},{"key":"ref_153","unstructured":"GBD 2015 HIV Collaborators (2016). Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: The Global Burden of Disease Study 2015. Lancet HIV, 3, e361\u2013e387."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0140-6736(04)17487-4","article-title":"The time has come for common ground on preventing sexual transmission of HIV","volume":"364","author":"Halperin","year":"2004","journal-title":"Lancet"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jama.2018.2093","article-title":"The global HIV epidemic: What will it take to get to the finish line?","volume":"319","author":"Katz","year":"2018","journal-title":"JAMA"},{"key":"ref_156","unstructured":"Sacrist\u00e1n, J.A., and Gutierrez, J.A. (2016). Reflexiones sobre la Ciencia en Espa\u00f1a, Uni\u00f3n Editorial. (In Spanish)."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.medcli.2013.01.034","article-title":"Healthcare resources restrictions and HIV infection","volume":"141","author":"Soriano","year":"2013","journal-title":"Med. Clin."},{"key":"ref_158","unstructured":"Dinden, T. (2017, February 21). Over-Regulation Has Criminalized the Practice of Medicine. Available online: www.zerohedge.com."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/6\/293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:31Z","timestamp":1760195191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/6\/293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":158,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["v10060293"],"URL":"https:\/\/doi.org\/10.3390\/v10060293","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]}}}